X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
eTheRNA will receive exclusive worldwide rights to commercialise a new library of novel ionizable lipids, co-developed with the research group of Prof. Bruno De Geest from Ghent University, for a new generation of lipid nanoparticle (LNP) formulations.
Lead Product(s): mRNA-based Immunotherapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Ghent University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2021
Details:
Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation.
Lead Product(s): TetraMix-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: VUB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2021
Details:
The grant will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic HPV16+ cancers such as head and neck cancer, cervical cancer, anogenital cancer.
Lead Product(s): mRNA cancer vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: $8.3 million Upfront Cash: Undisclosed
Deal Type: Funding March 22, 2021
Details:
The partnership will initially focus on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development.
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: ConserV Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 04, 2021
Details:
Proceeds of the financing will fund continued development and commercialization of proprietary mRNA technologies and a range of therapeutic products.
Lead Product(s): SARS-CoV-2 mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: LSP
Deal Size: $38.1 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2020
Details:
The new vaccine is intended specifically for populations at high risk. It is also planned to guard against potential viral mutations by targeting conserved epitopes of the entire CoV-2 genome.
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
